Myocardial bridging

Jorge R. Alegria, Joerg Herrmann, David Holmes, Amir Lerman, Charanjit Rihal

Research output: Contribution to journalArticle

272 Citations (Scopus)

Abstract

Myocardial bridging, a congenital coronary anomaly, is a clinical condition with several possible manifestations, and its clinical relevance is debated. This article reviews current knowledge about the anatomy, pathophysiology, clinical relevance, and treatment of myocardial bridging. Myocardial bridging is present when a segment of a major epicardial coronary artery, the 'tunnelled artery', runs intramurally through the myocardium. With each systole, the coronary artery is compressed. Myocardial bridging has been associated with angina, arrhythmia, depressed left ventricular function, myocardial stunning, early death after cardiac transplantation, and sudden death. Evidence indicates that the intima beneath the bridge is protected from atherosclerosis, and the proximal segment is more susceptible to development of atherosclerotic lesions because of haemodynamic disturbances. New techniques (e.g. intravascular ultrasonography and intracoronary Doppler studies) have revealed new characteristics and pathophysiologic processes such as diastolic flow abnormalities. Medical treatment generally includes β-blockers. Nitrates should be avoided because symptoms may worsen. Intracoronary stents and surgery have been attempted in selected patients. Additional research is needed to define patients in whom myocardial bridging is potentially pathologic, and randomized multicentre long-term follow-up studies are needed to assess the natural history, patient selection, and therapeutic approaches.

Original languageEnglish (US)
Pages (from-to)1159-1168
Number of pages10
JournalEuropean Heart Journal
Volume26
Issue number12
DOIs
StatePublished - Jun 2005

Fingerprint

Myocardial Bridging
Coronary Vessels
Interventional Ultrasonography
Myocardial Stunning
Systole
Heart Transplantation
Sudden Death
Natural History
Left Ventricular Function
Nitrates
Patient Selection
Stents
Cardiac Arrhythmias
Anatomy
Atherosclerosis
Myocardium
Therapeutics
Arteries
Hemodynamics
Research

Keywords

  • Anatomy
  • Blood flow
  • Myocardial bridging
  • Tunnelled artery
  • Ultrasound

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Myocardial bridging. / Alegria, Jorge R.; Herrmann, Joerg; Holmes, David; Lerman, Amir; Rihal, Charanjit.

In: European Heart Journal, Vol. 26, No. 12, 06.2005, p. 1159-1168.

Research output: Contribution to journalArticle

Alegria, Jorge R. ; Herrmann, Joerg ; Holmes, David ; Lerman, Amir ; Rihal, Charanjit. / Myocardial bridging. In: European Heart Journal. 2005 ; Vol. 26, No. 12. pp. 1159-1168.
@article{ea93d1216f8847128780fefe8c54fb05,
title = "Myocardial bridging",
abstract = "Myocardial bridging, a congenital coronary anomaly, is a clinical condition with several possible manifestations, and its clinical relevance is debated. This article reviews current knowledge about the anatomy, pathophysiology, clinical relevance, and treatment of myocardial bridging. Myocardial bridging is present when a segment of a major epicardial coronary artery, the 'tunnelled artery', runs intramurally through the myocardium. With each systole, the coronary artery is compressed. Myocardial bridging has been associated with angina, arrhythmia, depressed left ventricular function, myocardial stunning, early death after cardiac transplantation, and sudden death. Evidence indicates that the intima beneath the bridge is protected from atherosclerosis, and the proximal segment is more susceptible to development of atherosclerotic lesions because of haemodynamic disturbances. New techniques (e.g. intravascular ultrasonography and intracoronary Doppler studies) have revealed new characteristics and pathophysiologic processes such as diastolic flow abnormalities. Medical treatment generally includes β-blockers. Nitrates should be avoided because symptoms may worsen. Intracoronary stents and surgery have been attempted in selected patients. Additional research is needed to define patients in whom myocardial bridging is potentially pathologic, and randomized multicentre long-term follow-up studies are needed to assess the natural history, patient selection, and therapeutic approaches.",
keywords = "Anatomy, Blood flow, Myocardial bridging, Tunnelled artery, Ultrasound",
author = "Alegria, {Jorge R.} and Joerg Herrmann and David Holmes and Amir Lerman and Charanjit Rihal",
year = "2005",
month = "6",
doi = "10.1093/eurheartj/ehi203",
language = "English (US)",
volume = "26",
pages = "1159--1168",
journal = "European Heart Journal",
issn = "0195-668X",
publisher = "Oxford University Press",
number = "12",

}

TY - JOUR

T1 - Myocardial bridging

AU - Alegria, Jorge R.

AU - Herrmann, Joerg

AU - Holmes, David

AU - Lerman, Amir

AU - Rihal, Charanjit

PY - 2005/6

Y1 - 2005/6

N2 - Myocardial bridging, a congenital coronary anomaly, is a clinical condition with several possible manifestations, and its clinical relevance is debated. This article reviews current knowledge about the anatomy, pathophysiology, clinical relevance, and treatment of myocardial bridging. Myocardial bridging is present when a segment of a major epicardial coronary artery, the 'tunnelled artery', runs intramurally through the myocardium. With each systole, the coronary artery is compressed. Myocardial bridging has been associated with angina, arrhythmia, depressed left ventricular function, myocardial stunning, early death after cardiac transplantation, and sudden death. Evidence indicates that the intima beneath the bridge is protected from atherosclerosis, and the proximal segment is more susceptible to development of atherosclerotic lesions because of haemodynamic disturbances. New techniques (e.g. intravascular ultrasonography and intracoronary Doppler studies) have revealed new characteristics and pathophysiologic processes such as diastolic flow abnormalities. Medical treatment generally includes β-blockers. Nitrates should be avoided because symptoms may worsen. Intracoronary stents and surgery have been attempted in selected patients. Additional research is needed to define patients in whom myocardial bridging is potentially pathologic, and randomized multicentre long-term follow-up studies are needed to assess the natural history, patient selection, and therapeutic approaches.

AB - Myocardial bridging, a congenital coronary anomaly, is a clinical condition with several possible manifestations, and its clinical relevance is debated. This article reviews current knowledge about the anatomy, pathophysiology, clinical relevance, and treatment of myocardial bridging. Myocardial bridging is present when a segment of a major epicardial coronary artery, the 'tunnelled artery', runs intramurally through the myocardium. With each systole, the coronary artery is compressed. Myocardial bridging has been associated with angina, arrhythmia, depressed left ventricular function, myocardial stunning, early death after cardiac transplantation, and sudden death. Evidence indicates that the intima beneath the bridge is protected from atherosclerosis, and the proximal segment is more susceptible to development of atherosclerotic lesions because of haemodynamic disturbances. New techniques (e.g. intravascular ultrasonography and intracoronary Doppler studies) have revealed new characteristics and pathophysiologic processes such as diastolic flow abnormalities. Medical treatment generally includes β-blockers. Nitrates should be avoided because symptoms may worsen. Intracoronary stents and surgery have been attempted in selected patients. Additional research is needed to define patients in whom myocardial bridging is potentially pathologic, and randomized multicentre long-term follow-up studies are needed to assess the natural history, patient selection, and therapeutic approaches.

KW - Anatomy

KW - Blood flow

KW - Myocardial bridging

KW - Tunnelled artery

KW - Ultrasound

UR - http://www.scopus.com/inward/record.url?scp=20844451543&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20844451543&partnerID=8YFLogxK

U2 - 10.1093/eurheartj/ehi203

DO - 10.1093/eurheartj/ehi203

M3 - Article

C2 - 15764618

AN - SCOPUS:20844451543

VL - 26

SP - 1159

EP - 1168

JO - European Heart Journal

JF - European Heart Journal

SN - 0195-668X

IS - 12

ER -